

**Table 1:** Polymersomes forming copolymers properties and applications









|  | Copolymer   | Properties   | Applications   |
|--|---|--|--|
| Poly(ethylene oxide)-<br>Poly(propylene oxide) |    | Commercial availability, FDA approved <sup>7</sup>                   | None (limited stability)                                     |
| Poly(acrylic acid)-<br>polystyrene (PAA-PS)    |    | Ability to form large compound vesicular aggregates <sup>6,8,9</sup> | Potential drug delivery vector                               |
| Poly(ethylene oxide)-<br>polystyrene           |    | Ability to form large compound vesicular aggregates <sup>10</sup>    | Potential use in controlled release/ biomedical applications |
| Poly(acrylic acid)-<br>polybutadiene           |   | Ability to form large compound vesicular aggregates <sup>11</sup>    | None reported  |
| Poly(ethylene oxide)-<br>Poly(butadiene)       |  | Mechanical toughness, biological inertness, cross linkability        | NIR imaging contrast agent                                   |
| Poly(ethylene oxide)-<br>Poly(ethyl ethylene)  |  | Mechanical toughness, biological inertness <sup>5,12</sup>           | Toughener for epoxy resins                                   |
| Poly(ethylene oxide)-<br>Poly(butylene oxide)  |  | Selective permeability <sup>13,14</sup>                              | Drug delivery  |
| Poly(ethylene oxide)-<br>Poly(lactic acid)     |  | Biodegradability <sup>15</sup>                                       | Anticancer drug delivery                                     |

Table 1: cont.d







| Copolymer   | Properties   | Applications   |
|---|--|--|
| Poly(ethylene oxide)-<br>Polycaprolactone   |  <p>PEO PCL</p>     | Biodegradability<br>, slow release<br>kinetics <sup>15</sup>   |
| Poly(ethylene oxide)-<br>Poly(trimethylene carbonate)   |  <p>PEO PTMC</p>    | Biodegradability<br>, temperature-<br>sensitivity <sup>15</sup>  |
| Poly(2-ethyl-2-oxazoline)-<br>poly(dimethylsiloxane)-poly(2-ethyl-2-oxazoline)                              |  <p>PEtOz PDMS</p>  | Ability to<br>incorporate<br>membrane<br>proteins within<br>polymersomal<br>membrane <sup>27</sup>                                     |
| Polybutadiene-<br>(poly-L-glutamate)  |  <p>PBD PG</p>     | pH-sensitivity,<br>ability to<br>undergo helix-<br>coil transitions<br>without<br>affecting<br>polymersome<br>morphology <sup>16</sup> |
| Poly(2-<br>methacryloxyethyl<br>phosphorylcholine)<br>-poly(2-<br>(diisopropylamino)<br>ethyl methacrylate) |  <p>PMPC PDPA</p> | pH-sensitivity <sup>17</sup>   |
| Poly(γ-benzyl-L-<br>glutamate)-poly(L-<br>lysine)   |  <p>PBLG</p>      | Dendrimer, α-<br>helical<br>conformation <sup>35</sup>   |
|   |  | Anticancer drug<br>delivery,<br>delivery to the<br>CNS   |
|   |  | <i>In situ</i> gel<br>production for<br>drug delivery/<br>tissue engineering   |
|   |  | “Artificial cell”,<br>nanoreactor  |
|   |  | None reported  |
|   |  | Gene and drug<br>delivery  |
|   |  | Modelling of<br>proteins tertiary<br>structures  |

Table 1: cont.d






| Copolymer   | Properties  | Applications   |   |
|---|---|--|---|
| Poly(L-arginine)-<br>poly(L-leucine)  |    | pH sensitivity <sup>18</sup>   | Drug delivery   |
| Poly(2-<br>vinylpyridine)-<br>poly(ethylene<br>oxide)   |    | pH sensitivity <sup>19</sup>   | Controlled release  |
| Poly(acrylic acid)-<br>polystyrene-poly(4-<br>vinyl pyridine)   |   | pH-dependent<br>vesicle surface<br>chemistry <sup>20</sup>   | None reported   |
| Poly(ethylene<br>oxide)-<br>poly(2-<br>(diethylamino)ethyl<br>methacrylate- <i>stat</i> -<br>3-(trimethoxysilyl)<br>propyl<br>methacrylate) |  | pH-tunable<br>membrane<br>permeability,<br>self-cross-<br>linkability <sup>21</sup>                  | Support for<br>precious metal<br>catalyst   |
| Poly(acrylic acid)-<br>poly(distearin<br>acrylate)  |  | pH-tunable<br>membrane<br>permeability,<br>generation of<br>multivesicle<br>assemblies <sup>22</sup> | Controlled<br>release,<br>model for<br>eukaryotic cells<br>and their internal<br>organelles |

Table 1: cont.d






| Copolymer   | Properties  | Applications   |   |
|---|---|--|---|
| Poly(L-arginine)-<br>poly(L-leucine)  |    | pH sensitivity <sup>18</sup>   | Drug delivery   |
| Poly(2-<br>vinylpyridine)-<br>poly(ethylene<br>oxide)   |    | pH sensitivity <sup>19</sup>   | Controlled release  |
| Poly(acrylic acid)-<br>polystyrene-poly(4-<br>vinyl pyridine)   |   | pH-dependent<br>vesicle surface<br>chemistry <sup>20</sup>   | None reported   |
| Poly(ethylene<br>oxide)-<br>poly(2-<br>(diethylamino)ethyl<br>methacrylate- <i>stat</i> -<br>3-(trimethoxysilyl)<br>propyl<br>methacrylate) |  | pH-tunable<br>membrane<br>permeability,<br>self-cross-<br>linkability <sup>21</sup>                  | Support for<br>precious metal<br>catalyst   |
| Poly(acrylic acid)-<br>poly(distearin<br>acrylate)  |  | pH-tunable<br>membrane<br>permeability,<br>generation of<br>multivesicle<br>assemblies <sup>22</sup> | Controlled<br>release,<br>model for<br>eukaryotic cells<br>and their internal<br>organelles |

Table 1: cont.d













| Copolymer  | Properties  | Applications   |
|--|---|--|
| Poly(ethylene oxide)-poly(methylphenylsilane)                          |    | Sensitivity to UV light <sup>23</sup><br>None reported   |
| Azobenzene-containing poly(methacrylate)-poly(acrylic acid)            |   | Sensitivity to UV light <sup>23</sup><br>None reported   |
| Poly(ethylene oxide)-poly(propylene sulphide)                          |  | Sensitivity to oxidation <sup>24</sup><br>Oxidative species and glucose sensitive delivery         |
| Poly(ethylene oxide)-SS-poly(propylene sulfide)                        |  | Sensitivity to reduction <sup>25</sup><br>Drug delivery  |
| Poly(2-methyloxazoline)-poly(dimethylsiloxane)-poly(2-methyloxazoline) |  | Ability to incorporate membrane proteins within polymersomal membrane <sup>26</sup><br>Nanoreactor |
| Poly(butadiene)-poly(L-lysine)   |  | Helical morphologies copolymer blocks <sup>32-34</sup><br>Drug delivery                            |

Table 1: cont.d

| Copolymer   | Properties  | Applications   |
|---|---|--|
| Poly(L-lysine)-poly(L-leucine)                                    |    | Controllable vesicle diameter, degradability <sup>29</sup><br>Mimicking tertiary structures of proteins              |
| Poly(L-glutamic acid)-poly(L-leucine)                             |    | Controllable vesicle diameter, degradability, stability in presence of serum proteins <sup>29</sup><br>None reported |
| Poly(butadiene)-poly( <i>N</i> -methyl-4-vinyl-pyridinium iodide) |   | Polymersomes formation through using a "single emulsion technique" <sup>30</sup><br>DNA delivery                     |
| Polystyrene-poly(L-isocyanoalanine(2-thiophen-3-yl-ethyl)amide)   |  | Selective permeability <sup>28</sup><br>Nanoreactor  |
| Polystyrene-poly(isocyano-L-alanine-L-alanine)                    |  | Helical morphologies copolymer blocks <sup>32</sup><br>None reported   |
| Polystyrene-poly(isocyano-L-alanine-L-histidine)                  |  | Helical morphologies copolymer blocks <sup>32</sup><br>None reported   |